FY2028 EPS Estimates for IONS Reduced by Leerink Partnrs

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) - Leerink Partnrs reduced their FY2028 earnings per share estimates for Ionis Pharmaceuticals in a research note issued on Wednesday, November 6th. Leerink Partnrs analyst M. Foroohar now expects that the company will post earnings per share of $1.32 for the year, down from their prior forecast of $1.47. Leerink Partnrs has a "Strong-Buy" rating on the stock. The consensus estimate for Ionis Pharmaceuticals' current full-year earnings is ($3.73) per share.

Several other equities analysts have also issued reports on the stock. Wells Fargo & Company lowered their target price on shares of Ionis Pharmaceuticals from $82.00 to $77.00 and set an "overweight" rating for the company in a report on Thursday. TD Cowen lifted their price target on Ionis Pharmaceuticals from $54.00 to $59.00 and gave the stock a "buy" rating in a research report on Tuesday, July 23rd. The Goldman Sachs Group raised their price objective on shares of Ionis Pharmaceuticals from $33.00 to $37.00 and gave the company a "sell" rating in a research note on Friday, August 2nd. Jefferies Financial Group assumed coverage on shares of Ionis Pharmaceuticals in a research note on Tuesday, July 16th. They set a "buy" rating and a $75.00 target price on the stock. Finally, Needham & Company LLC restated a "buy" rating and issued a $60.00 price target on shares of Ionis Pharmaceuticals in a research note on Thursday. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $60.71.

Ionis Pharmaceuticals Stock Up 1.6 %

Shares of IONS stock traded up $0.60 during mid-day trading on Friday, reaching $39.06. 457,863 shares of the company's stock traded hands, compared to its average volume of 1,315,430. Ionis Pharmaceuticals has a 12 month low of $35.95 and a 12 month high of $54.44. The company has a market cap of $5.71 billion, a P/E ratio of -15.26 and a beta of 0.39. The company's 50-day moving average price is $40.82 and its 200-day moving average price is $42.93. The company has a quick ratio of 7.51, a current ratio of 7.61 and a debt-to-equity ratio of 4.67.

Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.95) EPS for the quarter, topping the consensus estimate of ($1.16) by $0.21. Ionis Pharmaceuticals had a negative net margin of 44.90% and a negative return on equity of 115.66%. The business had revenue of $134.00 million during the quarter, compared to analyst estimates of $128.99 million.

Institutional Investors Weigh In On Ionis Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the company. GAMMA Investing LLC lifted its stake in Ionis Pharmaceuticals by 83.9% in the third quarter. GAMMA Investing LLC now owns 664 shares of the company's stock worth $27,000 after acquiring an additional 303 shares during the period. nVerses Capital LLC bought a new position in shares of Ionis Pharmaceuticals during the second quarter valued at approximately $29,000. Itau Unibanco Holding S.A. purchased a new position in Ionis Pharmaceuticals during the second quarter valued at approximately $37,000. Mather Group LLC. raised its stake in Ionis Pharmaceuticals by 35.8% in the second quarter. Mather Group LLC. now owns 911 shares of the company's stock worth $39,000 after buying an additional 240 shares in the last quarter. Finally, Capital Performance Advisors LLP purchased a new stake in Ionis Pharmaceuticals during the third quarter worth $40,000. 93.86% of the stock is owned by institutional investors.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.